{"id":569715,"date":"2021-10-19T19:22:02","date_gmt":"2021-10-19T19:22:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=569715"},"modified":"2021-10-19T19:22:02","modified_gmt":"2021-10-19T19:22:02","slug":"cutaneous-lupus-erythematosus-pipeline-report-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-lupus-erythematosus-pipeline-report-analysis-by-delveinsight_569715.html","title":{"rendered":"Cutaneous Lupus Erythematosus Pipeline Report Analysis by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1634616687.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cutaneous Lupus Erythematosus Pipeline Report Analysis by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1634616687.png\" alt=\"Cutaneous Lupus Erythematosus Pipeline Report Analysis by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Cutaneous Lupus Erythematosus Pipeline<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s Cutaneous Lupus Erythematosus pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/6042b45676468827b4d06736c181cb5c.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Cutaneous Lupus Erythematosus pipeline report<\/a><\/strong> provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the Key Highlights from the Cutaneous Lupus Erythematosus Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">There are currently <strong>15+ drugs<\/strong> in the Cutaneous Lupus Erythematosus pipeline.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Cutaneous Lupus Erythematosus pipeline consists of therapies in different clinical phase stages, including <strong>SAR443122, BMS-986256, CBS004,<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Some of the companies actively working to improve the Cutaneous Lupus Erythematosus treatment landscape are <strong>Sanofi, Bristol-Myers Squibb, Centessa Pharmaceuticals, HOTH, Biogen, Centessa Pharmaceuticals, Merck,<\/strong> and others.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Denali and Sanofi<\/strong> announced a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors, including peripherally restricted molecules such as DNL758 and CNS-penetrant molecules such as <strong>DNL788 (SAR443820).<\/strong><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>CBS004<\/strong> is being developed and investigated in the preclinical stage by<strong> Centessa Pharmaceuticals.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a detailed analysis of the pipeline landscape @<strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Cutaneous Lupus Erythematosus Pipeline Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous Lupus Erythematosus: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Cutaneous Lupus Erythematosus (CLE) is an autoimmune disease that can manifest as different skin disease or a systemic lupus erythematosus symptom. Cutaneous lupus erythematosus (LE) can occur as a complication of Systemic Lupus Erythematosus (SLE) or independently of SLE.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous Lupus Erythematosus Symptoms<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">CLE has a broad clinical spectrum, ranging from isolated discoid plaques to widespread skin lesions. Acute cutaneous lupus erythematosus is characterized by transient erythematous patches that occur in conjunction with a flare of systemic lupus erythematosus.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous Lupus Erythematosus Treatment<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">CLE treatment aims to improve skin appearance, limit scarring, and prevent new skin lesions. Sun protection is a critical preventative measure for avoiding skin lupus flares caused by UVB radiation. Pharmacological inhibition of both adaptive and innate immune responses is effective in the treatment of CLE patients. Local therapy, topical steroids, intralesional steroids, systemic therapy, antimalarials, immune modulators such as methotrexate, mycophenolate, dapsone, ciclosporin, and systemic corticosteroids are examples of specific measures.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous Lupus Erythematosus Pipeline Analysis: Drug Profiles&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>SAR443122: Sanofi<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Product Description<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">SAR443122 (DNL758) is a small molecule RIPK1 inhibitor that does not enter the brain. RIPK1 is a tumor necrosis factor (TNF) receptor pathway signaling protein that regulates inflammation and cell death.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Phase II<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>NCT04781816:<\/strong> Sanofi began a randomized, double-blind, placebo-controlled proof-of-concept study in April 2021 to assess the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid\/chronic cutaneous lupus erythematosus. The primary goal of this study is to determine the efficacy of SAR443122 in patients with cutaneous lupus erythematosus (CLE).<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous Lupus Erythematosus Pipeline Therapies and Key Companies<\/strong>&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">SAR443122: Sanofi<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">BMS-986256: Bristol-Myers Squibb<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CBS004: Centessa Pharmaceuticals<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">Find out the emerging therapies and companies @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-lupus-erythematosus-cle-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Cutaneous Lupus Erythematosus Clinical Trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous Lupus Erythematosus Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Product Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Monotherapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Combination Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Stage<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discovery<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-Clinical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase I<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase II<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Phase III<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-registration<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Route of Administration<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Inhalation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intravenous<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Oral<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Subcutaneous<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Molecule Type<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Small Molecule<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Stem Cell Therapy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gene Therapy<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Targets<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immune System<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Multiple Kinase<\/p>\n<\/li>\n<\/ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>By Mechanism of Action<\/strong><\/p>\n<\/li>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Protease Inhibitors<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Immunomodulatory<\/p>\n<\/li>\n<\/ul>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Scope of the Report<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Coverage:<\/strong> Global<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous Lupus Erythematosus Key Players:<\/strong> Sanofi, Bristol-Myers Squibb, Centessa Pharmaceuticals, HOTH, Biogen, Centessa Pharmaceuticals, Merck, among others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cutaneous Lupus Erythematosus Pipeline Therapies:<\/strong> SAR443122, BMS-986256, CBS004, and others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<div style=\"text-align: justify;\" dir=\"ltr\" align=\"left\">\n<table>\n<colgroup>\n<col width=\"76\" \/>\n<col width=\"548\" \/><\/colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\">1.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">2.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">3.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus: Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">4.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">5.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus Late Stage Products (Pre-registration)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">6.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus Late Stage Products (Phase&nbsp; III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">7.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus Mid Stage Products (Phase&nbsp; II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">8.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus Early Stage Products (Phase&nbsp; I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">9.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus Pre-clinical and Discovery Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">10.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus Therapeutics Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">11.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">12.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus- Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">13.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Cutaneous Lupus Erythematosus- Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">14.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p dir=\"ltr\">15.<\/p>\n<\/td>\n<td>\n<p dir=\"ltr\">About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get in touch with our business executive for <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/due-diligence-services?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Healthcare Due Diligence Services<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key questions answered in the Cutaneous Lupus Erythematosus Pipeline Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">What are the treatments for Cutaneous Lupus Erythematosus?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many pharmaceutical companies are working on treatments for Cutaneous Lupus Erythematosus?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Which of these companies&#8217; pharmaceuticals is the most commonly used?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many Each company manufactures cutaneous Lupus Erythematosus medications?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many drugs are in the early, mid, or late stages of development for Cutaneous Lupus Erythematosus?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">How many of the currently being developed therapies can be used alone or in combination with other treatments?<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">What are the essential industry-industry and industry-academy collaborations, mergers and acquisitions, and licensing practices in Cutaneous Lupus Erythematosus?<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Related Reports<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/systemic-lupus-erythematosus-pipeline-insight?utm_source=Abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=spr\">Systemic Lupus Erythematosus Pipeline Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Get a comprehensive analysis of Systemic Lupus Erythematosus pipeline therapies and key companies, including <strong>GlaxoSmithKline, AstraZeneca, Biogen, Eli Lilly and Company, Xencor, Pfizer,<\/strong> among others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com\/_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Sandeep Joshi<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cutaneous-lupus-erythematosus-pipeline-report-analysis-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cutaneous-lupus-erythematosus-pipeline-report-analysis-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cutaneous Lupus Erythematosus Pipeline DelveInsight\u2019s Cutaneous Lupus Erythematosus pipeline report provides comprehensive coverage of the emerging drugs profiles, including clinical and nonclinical products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. DelveInsight&rsquo;s &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cutaneous-lupus-erythematosus-pipeline-report-analysis-by-delveinsight_569715.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,420,403,404],"tags":[],"class_list":["post-569715","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/569715","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=569715"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/569715\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=569715"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=569715"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=569715"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}